Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBio Ltd.

www.cbio.com.au

Latest From CBio Ltd.

BioNotebook: Targacept gone in reverse merger with Catalyst, plus five other deals

After a string of failures, Winston-Salem, North Carolina-based Targacept and its neuronal nicotinic receptor (NNR) therapeutics will be replaced by engineered human proteases for hemophilia and complement-mediated disorders in a reverse merger with privately-held Catalyst Biosciences in South San Francisco.

Gastrointestinal Cancer

New treatments for rheumatoid arthritis target underlying pathology

What do the French impressionist painter Pierre-Auguste Renoir and South African heart surgeon Christiaan Barnard have in common? They both depended on extreme manual dexterity in their chosen careers. How remarkable, then, that they both suffered from the debilitation condition, rheumatoid arthritis.

Gastrointestinal Dermatology

Ex-EMA head Thomas Lönngren must wait two years before joining pharma firms

Thomas Lönngren, the former head of the European Medicines Agency (EMA), will probably have to relinquish all or some of the commercial appointments that he has taken up since his departure from the agency. EMA said on 21 March that Mr Lönngren must wait two years before he takes up a position with the private sector pharmaceutical industry. The announcement follows controversy over a potential conflict of interest after Mr Lönngren joined private sector companies shortly after leaving the EMA.

Regulation

Start-Up Quarterly Statistics, Q3 2010

Biopharma, medical device, and in vitro diagnostics start-ups brought in a total of $780 million in Q3 2010, a 29% jump from the previous quarter and a 50% increase from Q3 2009. A total of eight start-up acquisitions closed in Q3, quite a jump from the first two quarters of 2010. The third quarter saw 14 biopharma alliances covering a wide range of therapeutic categories, the most popular indication being cancer.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • CBio Ltd.
  • Senior Management
  • Jason Yeates, CEO & Managing Dir.
    Dennis Feeney, MD, Executive Dir. & Pres., Global Dev. & Licensing
  • Contact Info
  • CBio Ltd.
    Phone: (61) 7 3841 4844
    Brisbane Technology Park
    85 Brandl St.
    Eight Mile Plains, 4113
    Australia
UsernamePublicRestriction

Register